Impact of Tyrosine Kinase Inhibitor Starting Dose on Outcomes in Patients With Non-Small Cell Lung Cancer.
Emily MiaoNagashree SeetharamuKevin SullivanStephen EngChung-Shien LeePublished in: Journal of pharmacy practice (2019)
Patients who initiated TKI therapy at a RD did not have different PFS and 15-month survival outcomes than patients who initiated TKI therapy at the FDA SD.